Michelle Wegscheid, an MD/PhD trainee in the Neurosciences Program at Washington University, successfully defended her PhD thesis titled “Genetic risk factors for neurodevelopmental disorders: Insights from hiPSC-cerebral organoids.” Michelle conducted her PhD training in the laboratory of Dr. David H. Gutmann at the Washington University Neurofibromatosis (NF) Center, where she worked to define how distinct […]
Month: July 2020
New Targets for Childhood Brain Tumors Identified
Neurons, immune cells work together to promote tumor growth in neurofibromatosis type 1 Children with the genetic condition neurofibromatosis type 1 (NF1) can develop brain and nerve tumors. If a tumor develops within the optic nerve, which connects the eye and the brain, the child may lose his or her vision. New research at Washington […]
UPDATE: NF Clinical Trials – Summer 2020
Check out the NF Clinical Trials section of our website, which was recently updated to include current NF-related trials from clinicaltrials.gov. Some new studies that have been added are: NF1 Clinical Trials: Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults (NF105-CABO) SARC031: […]
The “Emerging Field of Cancer Neuroscience”
As an outgrowth of a seminal meeting at the Cold Spring Harbor Laboratory Banbury Center in December 2019, a white paper contributed to by Dr. David H. Gutmann, MD, PhD, FAAN, outlined the new field of “cancer neuroscience”. This emerging scientific discipline is built on the idea that the nervous system normally controls the development, […]